8-K: Elicio Therapeutics Reports Q3 2026 Results, Advances Cancer Immunotherapy

Elicio Therapeutics announced third quarter 2026 financial results and provided updates on its AMPLIFY-7P trial, preclinical data, and planned Phase 1 studies for KRAS-driven cancers.

Summary

• Elicio Therapeutics reported financial results for the quarter ended September 30, 2026.
• The company presented new Phase 2 AMPLIFY-7P trial analyses showing reduced risk of recurrence or death in pancreatic cancer patients.
• Preclinical data for AMP-CpG (ELI-004) demonstrated significant tumor responses in animal models.
• A Phase 1 study combining camupepimut with daraxonrasib is targeted to initiate in Q4 2026 for metastatic pancreatic cancer.
• Research and development expenses were $4.9 million for Q3 2026, a slight decrease from $5.0 million in Q3 2025.
• General and administrative expenses increased to $3.6 million in Q3 2026 from $3.0 million in Q3 2025.
• Net loss for Q3 2026 was $8.0 million, an improvement from $10.1 million in Q3 2025.
• Cash and cash equivalents stood at $30.9 million as of September 30, 2026, with operations expected to be supported into Q2 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, highlighting promising clinical data and strategic advancements, while acknowledging the inherent risks in clinical-stage biotechnology.

Positives

• Phase 2 AMPLIFY-7P trial analyses showed a 49% reduction in risk of disease recurrence or death in ctDNA-negative patients and a 43% reduction in ctDNA-positive patients.
• A supportive multivariable analysis for AMPLIFY-7P estimated a 53% reduction in the hazard of recurrence or death (HR 0.47; p=0.0086).
• Preclinical data for AMP-CpG (ELI-004) showed complete tumor responses in 50% of treated animals in head and neck cancer models and 100% in melanoma models.
• Net loss decreased to $8.0 million in Q3 2026 from $10.1 million in Q3 2025.
• Cash and cash equivalents increased to $30.9 million as of September 30, 2026, from $18.6 million at the end of 2025.
• The company raised net proceeds of $4.3 million in Q3 2026 through its at-the-market program.
• The company raised net proceeds of approximately $13.6 million in July 2026 through a registered direct offering.

Negatives

• The AMPLIFY-7P trial did not meet its primary disease-free survival (DFS) endpoint in the intent-to-treat population.
• General and administrative expenses increased by $0.6 million in Q3 2026 compared to Q3 2025, primarily due to increased personnel and professional fees.
• The company's cash and cash equivalents are expected to support operations only into the second quarter of 2027, suggesting potential future financing needs.

Risks

• The company's ability to continue as a going concern is dependent on its ability to secure additional financing.
• The risks associated with clinical trials, including the timing and outcome of planned trials, are significant.
• The development and commercialization of product candidates are subject to numerous risks and uncertainties.
• New factors may emerge that could impact the business, and it is not possible to predict all such factors or their impact.

Future Outlook

The company expects its current cash and cash equivalents to support operations into the second quarter of 2027. A Phase 1 study evaluating camupepimut in combination with daraxonrasib is targeted to initiate in Q4 2026.

Management Comments

• We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward latestage development and refine our Phase 3 strategy in adjuvant PDAC.
• The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.
• These findings provide compelling signals that will help guide patient stratification and dosing in the planned Phase 3 adjuvant study.
• We are also enthusiastic about the opportunity to combine camupepimuts potent KRASspecific immune activation together with direct RAS inhibition in a planned Phase 1 study in metastatic PDAC, evaluating camupepimut with daraxonrasib, with or without nivolumab.
• Together, these efforts underscore camupepimuts therapeutic potential across the pancreatic cancer treatment continuum, where substantial unmet medical needs remain.

Industry Context

StockSavvy.ai notes that Elicio Therapeutics is operating in the highly competitive and rapidly evolving field of oncology drug development, specifically focusing on immunotherapies for KRAS-driven cancers. The company's strategy of developing 'off-the-shelf' immunotherapies aims to address the cost and accessibility challenges of personalized approaches, a trend gaining traction in the industry.

Comparison to Industry Standards

• The reported Phase 2 AMPLIFY-7P trial results, while not meeting the primary endpoint in the intent-to-treat population, showed statistically significant improvements in risk reduction for specific patient subgroups (ctDNA negative, ctDNA positive, no prior radiation). This level of subgroup analysis is common in early-stage oncology trials to identify potential patient populations for further development.
• The preclinical data showing high complete response rates (50-100%) in animal models for AMP-CpG (ELI-004) aligns with industry benchmarks for promising early-stage drug candidates, though translation to human efficacy is a significant hurdle.
• The planned Phase 1 combination study of camupepimut with daraxonrasib and nivolumab reflects a common industry strategy of exploring combination therapies to enhance efficacy in difficult-to-treat cancers like metastatic PDAC, where single-agent therapies often have limited success.

Stakeholder Impact

• Shareholders: The company's financial position and future prospects, including potential need for further capital raises, will impact shareholder value. Positive clinical data may boost confidence, while the short cash runway presents a risk.
• Employees: Continued R&D and clinical development efforts suggest ongoing employment opportunities, but financial stability is crucial for long-term job security.
• Patients: Advancements in clinical trials for camupepimut and AMP-CpG offer potential new treatment options for KRAS-driven cancers, addressing unmet medical needs.

Next Steps

• Initiate a Phase 1 study evaluating camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC in Q4 2026.
• Continue presenting Phase 2 AMPLIFY-7P clinical and translational findings at SITC 2026.
• Continue presenting new preclinical data on AMP-CpG (ELI-004) at SITC 2026.
• Advance camupepimut toward late-stage development and refine Phase 3 strategy in adjuvant PDAC.
• Continue the investigator-initiated Phase 1 neoadjuvant study of camupepimut.

Key Dates

Recommendation

The company shows promising clinical data and strategic progress in a critical area of cancer research. However, the failure to meet the primary endpoint in the AMPLIFY-7P trial for the overall population, coupled with a limited cash runway extending only into Q2 2027, introduces significant risk. While subgroup data is encouraging, further validation and successful fundraising are necessary. Therefore, a 'hold' recommendation is appropriate, pending clearer visibility on Phase 3 strategy success and financial sustainability.

Keywords

immunotherapies, KRAS-driven cancers, pancreatic cancer, clinical trials, biotechnology, oncology, drug development, Phase 2 trial